Sixth Street, along with KKR, invested $1 billion in newly issued convertible preferred equity in BridgeBio Pharma, a commercial-stage, multiproduct biopharmaceutical company focused on developing medicines for genetic conditions. Sixth Street was the lead investor.
Sixth Street is a global investment firm with more than $130 billion in assets under management and committed capital.
The S&C team representing Sixth Street included Ari Blaut, Pete Jones, Alan Fishman, Taylor Apodaca and Morgan Smiley.